ecrin-mdr-crcClinical2009Metastatic Colorectal CancerColorectal cancer metastaticPatients with chemotherapy-refractory metastatic colorectal cancerColorectal NeoplasmsCancerMetastatic Colorectal CancerPatients With Chemotherapy-refractory Metastatic Colorectal CancerColorectal Cancer MetastaticColorectal NeoplasmsCancerInterventionalhttps://newmdr.ecrin.org/Study/2074647AustriaGermany7CytavisCY-503ColorectalAviscuminePhase IIMetastaticDouble-blindRandomisedMulticenterControlledECRIN MDRTerminatedfalseCY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal CancerThis trial is designed as a phase II evaluation of the effect of CY-503 or placebo on progression free survival (PFS) defined as the time from start of treatment until the objective observation of progressive disease (PD) or death from any course in patients with chemotherapy-refractory metastatic colorectal cancer.2009-07-152074647NCT009327242008-005536-32